We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

While Eli Lilly missed on both the top and bottom lines in its Q3 financial results, a look at its sales figures -- and ...

Eli Lilly’s stock heads for biggest selloff in more than three years after sales of anti-obesity drugs Mounjaro and Zepbound ...

Eli Lilly and Company disappointed with missed earnings, lower guidance. Click here for my review of LLY Q3 earnings and a ...

Concerns about Lilly's Q3 update are overblown. Lilly's impressive growth story remains intact. The stock's valuation is attractive, factoring in anticipated growth over the next several years.

We expect Eli Lilly’s P/E ratio in 2025 to be 60 with an EPS of ... to $27.12 billion justifies this substantial increase in stock price. With an EPS of $25.97 and a P/E ratio of 50 in 2028 ...

U.S. stock indexes edged lower Wednesday after drops for Eli Lilly and chip companies overshadowed a jump for Google’s parent ...

Leerink Partners analyst David Risinger said separately that although Lilly’s results were disappointing, he is keeping his ...

Lilly has been having a great run. It is up ~38% year to date and up ~60% over the last year. However, with a P/E ratio of just over 67, the stock certainly isn't cheap. Seeking Alpha analyst ...

Leerink Partners analyst David Risinger said separately that although Lilly’s results were disappointing, he is keeping his “outperform” rating on the stock. He noted that Lilly “is just ...

INDIANAPOLIS (AP) — Eli Lilly is dialing back its 2024 forecast after underwhelming Wall Street with third-quarter earnings and sales from two key drugs that missed expectations. The drugmaker ...

Leerink Partners analyst David Risinger said separately that although Lilly’s results were disappointing, he is keeping his “outperform” rating on the stock. He noted that Lilly “is just ...